Biomerica Company Insiders

BMRA Stock  USD 0.70  0.08  12.90%   
Biomerica's insiders are aggressively buying. The analysis of insiders' sentiment of trading Biomerica stock suggests that vertually all insiders are extremely bullish at this time. Biomerica employs about 64 people. The company is managed by 7 executives with a total tenure of roughly 54 years, averaging almost 7.0 years of service per executive, having 9.14 employees per reported executive.
Zackary Irani  Chairman
Chairman, CEO and Pres

Insider Sentiment 100

 Aggressively Buying

 
Selling
 
Buying

Latest Trades

2023-05-24Zackary S IraniAcquired 500 @ 1.61View
2023-05-12Zackary S IraniAcquired 1700 @ 1.17View
2023-05-09Zackary S IraniAcquired 300 @ 1.39View
2023-04-28Zackary S IraniAcquired 1800 @ 1.34View
2023-04-26Zackary S IraniAcquired 7000 @ 1.26View
2023-01-27Allen BarbieriAcquired 1538 @ 2.94View
2023-01-26Catherine CosteAcquired 2190 @ 2.96View
2023-01-24Zackary S IraniAcquired 2000 @ 2.81View
Monitoring Biomerica's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Biomerica. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Biomerica Stock refer to our How to Trade Biomerica Stock guide.

Biomerica Management Team Effectiveness

The company has return on total asset (ROA) of (0.3854) % which means that it has lost $0.3854 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7648) %, meaning that it created substantial loss on money invested by shareholders. Biomerica's management efficiency ratios could be used to measure how well Biomerica manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.72. The current year's Return On Capital Employed is expected to grow to -0.99. At present, Biomerica's Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Intangible Assets is expected to grow to about 273.3 K, whereas Total Assets are forecasted to decline to about 7.4 M.
The current year's Common Stock Shares Outstanding is expected to grow to about 20.3 M, whereas Net Loss is projected to grow to (6.1 M).

Biomerica Workforce Comparison

Biomerica is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 1,440. Biomerica holds roughly 64.0 in number of employees claiming about 4% of equities under Health Care industry.

Biomerica Profit Margins

The company has Profit Margin (PM) of (1.12) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.76) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.76.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.120.13
Significantly Down
Slightly volatile

Biomerica Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Biomerica insiders, such as employees or executives, is commonly permitted as long as it does not rely on Biomerica's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Biomerica insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Biomerica Notable Stakeholders

A Biomerica stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Biomerica often face trade-offs trying to please all of them. Biomerica's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Biomerica's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Zackary IraniChairman, CEO and PresProfile
Gary CPAPrincipal CFOProfile
Allen BarbieriIndependent DirectorProfile
Hans BoehringerVP RDProfile
Steven SloanCFO TreasurerProfile
Lucy LiuDirector OperationsProfile
Robert CarlsonChief OfficerProfile

About Biomerica Management Performance

The success or failure of an entity such as Biomerica often depends on how effective the management is. Biomerica management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Biomerica management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Biomerica management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.76)(0.72)
Return On Capital Employed(1.04)(0.99)
Return On Assets(0.74)(0.71)
Return On Equity(1.04)(0.99)
Please note, the presentation of Biomerica's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Biomerica's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Biomerica's management manipulating its earnings.

Biomerica Workforce Analysis

Traditionally, organizations such as Biomerica use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Biomerica within its industry.

Biomerica Manpower Efficiency

Return on Biomerica Manpower

Revenue Per Employee84.6K
Revenue Per Executive773.6K
Net Loss Per Employee93.4K
Net Loss Per Executive854K
Working Capital Per Employee86.4K
Working Capital Per Executive789.6K

Complementary Tools for Biomerica Stock analysis

When running Biomerica's price analysis, check to measure Biomerica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biomerica is operating at the current time. Most of Biomerica's value examination focuses on studying past and present price action to predict the probability of Biomerica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biomerica's price. Additionally, you may evaluate how the addition of Biomerica to your portfolios can decrease your overall portfolio volatility.
FinTech Suite
Use AI to screen and filter profitable investment opportunities
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing